ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
ENA Respiratory has received AUD $2.98 million in funding from Biointelect Venturer to conduct a Phase Ib clinical trial for its INNA-051 nasal spray. The study will evaluate the safety and efficacy of the treatment in asthma patients to help prevent complications from respiratory viral infections.
Why it matters
This development represents a significant step in creating preventative treatments for high-risk populations prone to severe respiratory viral complications.
MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company
MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral infections in at-risk populations, today announces it has been awarded AUD $2,980,000 in funding from Australia’s Biointelect Venturer as part of its inaugural funding round.
The funding will support a first-in-patients study in Australia of INNA-051, in patients with asthma.
The Phase Ib study (ENA-A-04) will be a randomised, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intranasal INNA-051 in adults with asthma. The trial is expected to start in Q1 2027.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in